Occudo Quantitative Strategies LP Madrigal Pharmaceuticals, Inc. Transaction History

Occudo Quantitative Strategies LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$146.04 - $225.78 $397,082 - $613,895	2,719 New	2,719 $397,000
Q3 2022 Nov 14, 2022	BUY	$60.57 - $79.51 $148,033 - $194,322	2,444 Added 73.06%	5,789 $376,000
Q2 2022 Aug 15, 2022	BUY	$58.04 - $100.2 $194,143 - $335,169	3,345 New	3,345 $239,000
Q4 2021 Feb 14, 2022	SELL	$72.34 - $95.09 $330,159 - $433,990	-4,564 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$78.35 - $105.02 $541,711 - $726,108	-6,914 Reduced 60.24%	4,564 $364,000
Q2 2021 Aug 16, 2021	BUY	$97.2 - $137.59 $383,259 - $542,517	3,943 Added 52.33%	11,478 $1.12 Million
Q1 2021 May 14, 2021	SELL	$108.54 - $125.2 $331,372 - $382,235	-3,053 Reduced 28.83%	7,535 $881,000
Q4 2020 Feb 16, 2021	BUY	$110.06 - $133.7 $1.17 Million - $1.42 Million	10,588 New	10,588 $1.18 Million

296

22M

819K

640K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.94B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Occudo Quantitative Strategies LP, based on Form 13F filings with the SEC.

Stay updated on Occudo Quantitative Strategies LP with notifications on news.